Compare LYFT Inc (LYFT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Recursion Pharmaceuticals Inc — how do they compare? LYFT Inc trades at $16.24 (market cap $6.11B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: LYFT Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 13,504,560). Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| LYFT | RXRX | |
|---|---|---|
Market Cap | $6.11B | $2.14B |
Volume | 13,504,560 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $24.57 | $6.79 |
52-Week Low | $12.65 | $2.84 |
Typical Hold Time | 47 Days | 22 Days |
Enterprise Value | $5.57B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.27, up 4.29% with bullish technical signals from moving averages and ADX indicators. The company shows remarkable financial improvement with 2025 revenue of $6.32B and net income of $2.84B, achieving a 45.02% profit margin. Recent developments include European expansion and a $272.5M legal settlement. Valuation metrics appear attractive with P/E of 2.35 and P/S of 0.96, though EV/EBITDA remains elevated at 34.55.
Lyft presents a mixed investment case with strong profitability growth offset by competitive pressures and regulatory risks. The stock trades below analyst consensus target of $18.07, offering potential upside, but faces challenges from driver classification lawsuits and market saturation concerns. Recent earnings misses and high RSI levels suggest near-term volatility despite positive cash flow trends and institutional support.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
